Previous 10 | Next 10 |
Under Priority Review status, the FDA accepts Karyopharm Therapeutics' (NASDAQ: KPTI ) supplemental marketing application seeking approval to use Xpovio (selinexor) to treat adults with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior therapies. More...
NEWTON, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) seeking accelerated ...
NEWTON, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 9 th Annual SVB Leerink Global Health...
Don't let schooling interfere with your education ."- Mark Twain Busted IPO Forum model portfolio holding Karyopharm Therapeutics ( KPTI ) reported Q4 results late this week. This report shows the company continues to make impressive progress with its initial rollout with recently appro...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Image source: The Motley Fool. Karyopharm Therapeutics Inc (NASDAQ: KPTI) Q4 2019 Earnings Call Feb 13, 2020 , 8:30 a.m. ET Operator Continue reading
Karyopharm Therapeutics Inc. (KPTI) Q4 2019 Earnings Conference Call February 12, 2020 8:30 AM ET Company Participants Ian Karp - Vice President, Investor and Public Relations Michael Kauffman - Chief Executive Officer Mike Mason - Chief Financial Officer Perry Monaco - Senior ...
The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2019 Q4 earnings Read more ...
Karyopharm Therapeutics (NASDAQ: KPTI ): Q4 GAAP EPS of -$0.76 misses by $0.08 . More news on: Karyopharm Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- XPOVIO Net Product Sales of $17.7 Million for Fourth Quarter and $30.5 Million for Full Year 2019 -- -- XPOVIO Prescription Demand Increased by 65% in Fourth Quarter 2019 Compared to Third Quarter 2019 -- -- sNDA for Selinexor in DLBCL Submitted to FD...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...